Diligence memo · auto-generated · as of July 3, 2026
Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Salarius Pharmaceuticals, Inc. operates in Biotechnology, based in Houston.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Salarius Pharmaceuticals, Inc. has raised $35M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2014-07-23.
Most recent recorded round closed around 2024-12-27.
Valuation (modeled)modeled
Provath models Salarius Pharmaceuticals, Inc. at approximately $58M (range $20M–$94M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.34× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 42 months.
Last raise 18 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 77% of Biotechnology peers (4293 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.